T. SEGOVIA GÓMEZ, M. BERMEJO MARTINEZ, R. MA BONILLA SÁNCHEZ and I. TOUME(1), N. PIELENSTICKER(2) (1)University Hospital Puerta de Hierro Majadahonda Community of Madrid, Spain (2) Urgo GmbH, Sulzbach, Germany

1. SEQUENTIAL TREATMENT OF CHRONIC WOUNDS
WITH HYDRO-DESLOUGHING DRESSING* AND
TLC-NOSF DRESSING*
T. SEGOVIA GÓMEZ, M. BERMEJO MARTINEZ, R. MA BONILLA SÁNCHEZ
and I. TOUME(1),
N. PIELENSTICKER(2)
(1)University Hospital Puerta de Hierro Majadahonda Community of Madrid, Spain
(2) Urgo GmbH, Sulzbach, Germany
*Brand names: the hydro-desloughing dressing is UrgoClean®
and the TLC-NOSF dressing is UrgoStart ®

2. INTRODUCTION
The incidence of venous and arterial chronic wounds is a recognised type, as are the
different phases that are required to complete a correct healing process so that the treatment
of the wound is not prolonged.
Carrying out desloughing and activating the granulation phase, followed by rapid, effective
epithelialisation, are of vital importance because the products used for these functions must
be specific and must also display evident efficacy.
The new technologies applied to the wound bed, based on CAH/MET (moist environment
treatment), in its different phases, now offer products which meet the needs of professionals
for the different phases mentioned above by desloughing the wound bed and accelerating the
healing process.

3. D0 Treatment with
hydro-desloughing dressing*
Integrated treatment with hydro-desloughing and TLC-NOSF dressings*
87 year-old patient referred to the General Surgery Department for evaluation and
treatment of a vascular ulcer present for 4 months.
Personal history
Allergic to Aspirin
Has worn a pacemaker since 1984
Anticoagulated with Sintron
DESCRIPTION OF CASE 1
D45 Treatment with
TLC-NOSF dressing*
D72 Treatment with
TLC-NOSF dressing*
*Brand names: the hydro-desloughing dressing is UrgoClean®
and the TLC-NOSF dressing is UrgoStart ®

4. Integrated treatment with hydro-desloughing dressing*
79 year-old patient referred to the UHC (Multidisciplinary Wounds Unit), Department of
General Surgery, for valuation and treatment of vascular ulcers on the lower limbs.
Personal history
Arterial hypertension, positive hepatitis C virus, paroxystic articular fibrillation,
Hypothyroidism, iron-deficiency anaemia, repeated pneumonia with home oxygen,
Ex smoker and ex drinker.
DESCRIPTION OF CASE 2
D0 D13 D80

5. Integrated treatment with TLC-NOSF dressing*
79 year-old woman. Referred from her health centre for assessment of an ulcer on the left
knee, present for 15 days, following a trauma.
Personal history
No adverse drug reactions
Arterial hypertension
Nephrectomy due to malignant neoplasia.
DESCRIPTION OF CASE 3
D0 D38 D52

6. Treatment with hydro-desloughing fibre dressings provided optimum preparation of the
wound bed, which also facilitated the formation of granulation tissue. The dressing was
characterised by excellent absorption and also facilitated removal of practically all the slough
from the wound bed and contributed to desloughing totally atraumatic to the patient.
The TLC-NOSF dressing* facilitates optimisation of granulation and epithelialisation phases,
while providing the patient with totally atraumatic treatment in terms of dressing removal. The
skin surrounding the wound was not affected either.
CONCLUSION
• Nelzen O, Bergqvist D, Lindhagen A. Venous and non-venous leg ulcers: clinical history and appearance in a population study. Br J Surg
1994;81:182–7.• Schultz GS, Sibbald RG, Falanga V, et al. Wound bed preparation: a systematic approach to wound management. Wound Repair
Regen 2003; 11(2): Suppl S1-28.• Winter G. Formation of scab and the rate of epithelialisation of superficial wounds in the skin of the young
domestic pig. Nature 1962; 193: 293-294.• Hinman CAMH. Effect of air exposure and occlusion on experimental human skin wounds. Nature 1963;
200: 377-378• Viennet C, Bride J, Gabiot AC, Humbert Ph. Comparison of different wound dressings on cultured human fibroblasts and collagen
lattices. Journal of Wound Care. 2003. 12 (10): 385 – 390.• Schmutz JL, Meaume S, et al. Evaluation of the nano-oligosaccharide factor lipido-
colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. Internatiol Wounds Journal. Vol 5 nº2. •
Meaume, Sylvie et al. A randomized, controlled, doublé-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor
wound dressing in the local management of venous leg ulcers. Wound Repair and Regeneration. 2012.
*Brand names: the hydro-desloughing dressing is UrgoClean®
and the TLC-NOSF dressing is UrgoStart ®